Sponsor or institution
Clinical trials and research at Groupe Oncologie Radiotherapie Tete et Cou
As of November 12, 2026, Find a Trial lists 4 clinical trials run by Groupe Oncologie Radiotherapie Tete et Cou that are recruiting, in France. By phase: Phase 2 (3), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Ficerafusp alfa with nivolumab in platinum-refractory head and neck cancer | Phase 2 | Villejuif | Recruiting | Apr 14, 2026 |
| Ivonescimab with or without ligufalimab versus pembrolizumab as first-line treatment for recurrent/metastatic PD-L1-positive head and neck squamous cell carcinoma | Phase 3 | Le Havre | Recruiting | Dec 4, 2025 |
| MRG003 alone or with the PD‑1 drug pucotenlimab before chemoradiotherapy for locally advanced head and neck squamous cell carcinoma | Phase 2 | Villejuif | Recruiting | May 6, 2025 |
| Combining Avelumab with Standard Chemotherapy for Advanced Head and Neck Cancer | Phase 2 | Vandœuvre-lès-Nancy | Recruiting | Oct 15, 2024 |
All recruiting trials (4)
-
Ficerafusp alfa with nivolumab in platinum-refractory head and neck cancer
This study tests whether adding ficerafusp alfa to nivolumab helps patients with head and neck squamous cell cancer that progressed after platinum therapy.
-
Ivonescimab with or without ligufalimab versus pembrolizumab as first-line treatment for recurrent/metastatic PD-L1-positive head and neck squamous cell carcinoma
This study tests whether ivonescimab alone or with ligufalimab works as a first-line treatment for PD-L1‑positive recurrent or metastatic head and neck cancer, compared with pembrolizumab.
-
MRG003 alone or with the PD‑1 drug pucotenlimab before chemoradiotherapy for locally advanced head and neck squamous cell carcinoma
This trial will test whether giving MRG003 alone or together with the PD‑1 drug pucotenlimab before standard chemoradiotherapy helps people with locally advanced head and neck squamous cell carcinoma.
-
Combining Avelumab with Standard Chemotherapy for Advanced Head and Neck Cancer
This study is testing if adding avelumab to standard chemotherapy can help people with advanced head and neck cancer live longer and feel better.
Quick answers
How many clinical trials run by Groupe Oncologie Radiotherapie Tete et Cou are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in France. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.